Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab long-term extension in Japanese migraine patients
NCT05064371Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eptinezumab in migraine, sponsored by Lundbeck. Started Sep 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05064371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064371.